-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Outperform on Evolent Health, Raises Price Target to $7

Benzinga·11/06/2026 17:22:04
Oppenheimer analyst Michael Wiederhorn maintains Evolent Health (NYSE:EVH) with a Outperform and raises the price target from $6 to $7.